August 23, 2019

Notable Analyst Upgrades and Downgrades for Week of August 19, 2019




Upgrades:


AbbVie (NYSE:ABBV) was upgraded by investment analysts at Piper Jaffray Companies from a “neutral” rating to an “overweight” rating in a research report issued on Tuesday, The Fly reports. ABBV has been the topic of a number of other reports. Svb Leerink upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a report on Wednesday, June 26th. Leerink Swann upgraded shares of AbbVie to a “buy” rating in a report on Tuesday, July 2nd. Credit Suisse Group set a $78.00 target price on shares of AbbVie and gave the stock a “sell” rating in a report on Friday, April 26th. Wolfe Research upgraded shares of AbbVie from an “underperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Finally, ValuEngine downgraded shares of AbbVie from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 26th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $92.05. Read more …

Cardinal Health (NYSE:CAH) was upgraded by investment analysts at Guggenheim from a “neutral” rating to a “buy” rating in a report released on Tuesday, The Fly reports. Separately, ValuEngine upgraded shares of Cardinal Health from a “strong sell” rating to a “sell” rating in a report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $54.86. NYSE:CAH opened at $43.48 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.54 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $12.87 billion, a price-to-earnings ratio of 8.23, a PEG ratio of 1.43 and a beta of 1.28. The firm’s fifty day simple moving average is $45.58 and its 200 day simple moving average is $47.54. Cardinal Health has a twelve month low of $41.03 and a twelve month high of $58.31. Read more …

Wells Fargo & Co upgraded shares of Target (NYSE:TGT) from a market perform rating to an outperform rating in a report issued on Wednesday, The Fly reports. They currently have $115.00 price target on the retailer’s stock. A number of other research analysts have also issued reports on the company. Credit Suisse Group set a $90.00 price target on Target and gave the stock a buy rating in a research report on Thursday, May 23rd. Sanford C. Bernstein reiterated a mkt perform rating on shares of Target in a research report on Friday, May 3rd. Barclays reiterated a buy rating and set a $95.00 price target on shares of Target in a research report on Thursday, May 30th. Robert W. Baird set a $90.00 price objective on Target and gave the company a buy rating in a report on Monday, August 12th. Finally, Goldman Sachs Group began coverage on Target in a report on Thursday, July 11th. They issued a buy rating and a $102.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Target presently has a consensus rating of Buy and a consensus target price of $90.68. Read more …


Altria Group (NYSE:MO) was upgraded by equities research analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Friday, Marketbeat.com reports. The firm currently has a $44.00 price target on the stock. Morgan Stanley’s price objective points to a potential downside of 6.16% from the company’s previous close. A number of other analysts have also commented on the company. Royal Bank of Canada set a $68.00 price objective on Altria Group and gave the stock a “buy” rating in a report on Wednesday, July 31st. ValuEngine lowered Altria Group from a “hold” rating to a “sell” rating in a report on Wednesday, May 29th. TheStreet lowered Altria Group from a “b-” rating to a “c+” rating in a report on Wednesday, August 14th. Wells Fargo & Co reissued a “buy” rating on shares of Altria Group in a report on Friday, August 9th. Finally, Goldman Sachs Group lowered Altria Group from a “buy” rating to a “neutral” rating and set a $49.86 price objective for the company. in a report on Friday, July 12th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $60.74. Read more …



Downgrades:


Mizuho cut shares of Amgen (NASDAQ:AMGN) from a buy rating to a neutral rating in a research report released on Monday morning, BenzingaRatingsTable reports. They currently have $212.00 target price on the medical research company’s stock, up from their prior target price of $208.00. The analysts noted that the move was a valuation call.
Other equities research analysts have also issued reports about the stock. Credit Suisse Group reissued an outperform rating and set a $225.00 price objective (up from $202.00) on shares of Amgen in a report on Friday. Evercore ISI reissued a hold rating on shares of Amgen in a report on Sunday, August 11th. Citigroup reissued a buy rating on shares of Amgen in a report on Monday, August 12th. Piper Jaffray Companies set a $210.00 price objective on shares of Amgen and gave the company a buy rating in a report on Saturday, August 10th. Finally, Royal Bank of Canada reaffirmed a hold rating on shares of Amgen in a report on Sunday, August 11th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $212.94. Read more …

Royal Dutch Shell (LON:RDSB) was downgraded by investment analysts at Barclays to an “equal weight” rating in a research note issued on Tuesday, Borsen Zeitung reports. They currently have a GBX 3,100 ($40.51) price target on the stock, down from their previous price target of GBX 3,250 ($42.47). Barclays‘s price objective points to a potential upside of 34.26% from the company’s current price. RDSB has been the subject of a number of other research reports. UBS Group reiterated a “buy” rating on shares of Royal Dutch Shell in a research note on Monday. Morgan Stanley reiterated an “equal weight” rating and set a GBX 2,490 ($32.54) price target on shares of Royal Dutch Shell in a research note on Friday, July 12th. Royal Bank of Canada reiterated a “sector performer” rating on shares of Royal Dutch Shell in a research note on Friday, August 2nd. Berenberg Bank set a GBX 2,900 ($37.89) price target on Royal Dutch Shell and gave the company a “neutral” rating in a research note on Friday, August 2nd. Finally, HSBC cut their price target on Royal Dutch Shell from GBX 2,875 ($37.57) to GBX 2,780 ($36.33) and set a “buy” rating for the company in a research note on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of GBX 3,008.57 ($39.31). Read more …

MCCORMICK & CO /SH (NYSE:MKC) was downgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a report issued on Tuesday, The Fly reports. A number of other research analysts have also recently commented on the company. UBS Group set a $155.00 price objective on MCCORMICK & CO /SH and gave the company a “hold” rating in a report on Friday, June 28th. Zacks Investment Research upgraded MCCORMICK & CO /SH from a “sell” rating to a “hold” rating and set a $161.00 price target on the stock in a research note on Thursday, May 30th. Deutsche Bank set a $142.00 price target on MCCORMICK & CO /SH and gave the stock a “hold” rating in a research note on Friday, June 28th. Finally, Citigroup upped their price target on MCCORMICK & CO /SH from $155.00 to $166.00 and gave the stock a “neutral” rating in a research note on Friday, June 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $142.67. Read more …

Royal Bank of Canada cut shares of Kimco Realty (NYSE:KIM) from an outperform rating to a sector perform rating in a research note released on Thursday, BenzingaRatingsTable reports. They currently have $19.00 price target on the real estate investment trust’s stock. A number of other research analysts also recently issued reports on KIM. Zacks Investment Research upgraded shares of Kimco Realty from a sell rating to a buy rating and set a $19.00 price target for the company in a research note on Wednesday, May 1st. Raymond James downgraded shares of Kimco Realty from an outperform rating to a market perform rating and set a $18.17 price target for the company. in a research note on Tuesday, May 28th. Compass Point assumed coverage on shares of Kimco Realty in a research note on Thursday, August 15th. They issued a neutral rating and a $19.00 price target for the company. Citigroup lifted their price target on shares of Kimco Realty from $18.00 to $18.50 and gave the stock a neutral rating in a research note on Tuesday, July 30th. Finally, Bank of America upgraded shares of Kimco Realty from a neutral rating to a buy rating and lifted their price target for the stock from $19.00 to $21.00 in a research note on Tuesday, June 11th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $19.11. Read more …


No comments:

Post a Comment